SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy.

Drug Des Devel Ther · 2025 · PMC11869757 · PMID 40026336

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Compared to the vehicle group, no significant differences were observed in the low and medium-dose groups, while we observed that the mice in the high-dose group exhibited a decreasing trend in body weight after day 10.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.